Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,013 total articles

Prem AI Raises $100 Million Series A, Targets $500 Million Valuation

Prem AI Raises $100 Million Series A, Targets $500 Million Valuation

Prem AI, a Switzerland-based company that enables enterprises to run artificial intelligence models on their own private infrastructure, is raising $100 million in a Series A round and is targeting a valuation of at least $500 million. The company said it expects to complete the financing in the third quarter and counts hedge funds and law firms am…

HIVE Digital stock jumps after $220M GPU cloud agreement and Sweden data center purchase approval

HIVE Digital stock jumps after $220M GPU cloud agreement and Sweden data center purchase approval

Shares of HIVE Digital Technologies Ltd. rose sharply in premarket trading after the company disclosed a roughly $220 million, three-year GPU cloud contract through its BUZZ High Performance Computing unit and announced municipal approval to acquire a 32 MW data center in Boden, Sweden. The GPU deployment uses 2,304 NVIDIA Grace Blackwell GPUs in G…

U.S. Futures Edge Up as Middle East Interim Deal Eases Fed-Rate Worries; Movers Include FreeCast, Accenture, Novocure

U.S. Futures Edge Up as Middle East Interim Deal Eases Fed-Rate Worries; Movers Include FreeCast, Accenture, Novocure

U.S. equity futures rose on Thursday as markets reacted to news of an interim Middle East peace agreement that appeared to reduce some of the market's anxieties tied to the Federal Reserve's hawkish posture. At 0750 ET (11:50 GMT) futures contracts showed modest gains, with technology names among the strongest premarket performers. Several individu…

Novocure Shares Slide After TRIDENT Phase 3 Misses Primary Endpoint

Novocure Shares Slide After TRIDENT Phase 3 Misses Primary Endpoint

Novocure shares fell sharply in pre-market trading after the company disclosed that its Phase 3 TRIDENT trial did not achieve a statistically significant improvement in overall survival for newly diagnosed glioblastoma patients. The closely watched study showed nearly identical median survival between the trial arms, a development that removes a po…